Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2024
Immuno-oncology is a unique approach that uses the body’s immune system to fight cancer. These therapies activate an individual’s immune system, making it able to recognize cancer cells and destroy them. Immuno-oncology therapies provide long lasting anti-cancer benefits to patients who previously had very few treatment options available to them. These therapies work against a large number of cancer types. The technological advancements are helping the growth of immuno-oncology market. The biotechnology and pharmaceutical companies are striving to launch new and most effective therapies.
According to the report “Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2024”, the global immuno-oncology market is anticipated to reach US$ 135 Billion by 2024. The report provides a detailed analysis of the global immuno-oncology market. The report also provides the current and forecasted market for immuno-oncology.
Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immuno-oncology market. Moreover, the report provides the sales of major marketed immuno-oncology drugs.
The global immuno-oncology market has been segmented on the basis of type of product into monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2019 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme pro-drug therapy and radio immunotherapy).
The report also sheds light on the geographic segmentation of the global immuno-oncology market. In 2019, North America was estimated to account for the largest share. Presence of major players, increased awareness and better distribution mechanisms are some of the prominent factors that have led to North America being the market leader.
On the basis of type of cancer, the immuno-oncology market is dominated by Lung Cancer with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2024.
A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immuno-oncology programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.
The later part of the report discusses some of the prominent players in the global immuno-oncology market. Market share analysis of major players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immuno-oncology is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.
According to the report “Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2024”, the global immuno-oncology market is anticipated to reach US$ 135 Billion by 2024. The report provides a detailed analysis of the global immuno-oncology market. The report also provides the current and forecasted market for immuno-oncology.
Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immuno-oncology market. Moreover, the report provides the sales of major marketed immuno-oncology drugs.
The global immuno-oncology market has been segmented on the basis of type of product into monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2019 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme pro-drug therapy and radio immunotherapy).
The report also sheds light on the geographic segmentation of the global immuno-oncology market. In 2019, North America was estimated to account for the largest share. Presence of major players, increased awareness and better distribution mechanisms are some of the prominent factors that have led to North America being the market leader.
On the basis of type of cancer, the immuno-oncology market is dominated by Lung Cancer with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2024.
A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immuno-oncology programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.
The later part of the report discusses some of the prominent players in the global immuno-oncology market. Market share analysis of major players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immuno-oncology is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. IMMUNO-ONCOLOGY: OVERVIEW
4. MARKET DYNAMICS
4.1 Drivers
4.1.1 Increasing Cancer Incidences
4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
4.1.3 Growing Geriatric Population
4.1.4 High Healthcare Spending in Developed Economies
4.1.5 Strong Pipeline
4.1.6 Increasing Efficacy in a Wide Variety of Indications
4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
4.2 Challenges
4.2.1 Patent Expiry of Top-Selling Drugs
4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatments
4.2.3 Sky-High Development Costs of Cancer Immunotherapies
4.2.4 High Cost of Treatment
4.2.5 Lack of Awareness
4.3 Opportunities
4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival
4.3.3 CAR-T Therapies: The Future of Cancer Care
4.3.4 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies
5. GLOBAL IMMUNO-ONCOLOGY MARKET OUTLOOK 2024
6. GLOBAL IMMUNO-ONCOLOGY MARKET, BY PRODUCT CLASS
6.1 Monoclonal Antibodies (mAbs)
6.1.1 Naked Monoclonal Antibodies
6.1.1.1 Rituxan (Rituximab)
6.1.1.2 Avastin (Bevacizumab)
6.1.1.3 Herceptin (Trastuzumab)
6.1.2 Conjugated Monoclonal Antibodies
6.1.2.1 ADCETRIS (Brentuximab vedotin)
6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)
6.1.3 Bispecific Monoclonal Antibodies
6.1.3.1 Blincyto (Blinatumomab)
6.1.4 Others
6.2 Therapeutic Vaccines
6.2.1 Provenge
6.3 Immune Checkpoint Inhibitors
6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
6.3.1.1 Yervoy (Ipilimumab)
6.3.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand
6.3.2.1 Opdivo (Nivolumab)
6.3.2.2 Keytruda (Pembrolizumab)
6.4 Others
7. GLOBAL IMMUNO-ONCOLOGY MARKET, BY MAJOR INDICATIONS
7.1 Head & Neck Cancer
7.2 Lung Cancer
7.3 Melanoma
7.4 Lymphoma
7.5 Leukemia
7.6 Others
8. GLOBAL IMMUNO-ONCOLOGY MARKET, BY GEOGRAPHY
8.1 North America
8.2 Europe
8.3 Asia-Pacific
9. TRENDS & DEVELOPMENTS
9.1 Lucrative Investment Trend
9.2 Emergence of Targeted and Combination Therapies
9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
10. STRATEGIC COLLABORATIONS & ALLIANCES IN THE IMMUNO-ONCOLOGY INDUSTRY
11. PIPELINE ANALYSIS OF IMMUNO-ONCOLOGY
12. COMPETITIVE LANDSCAPE
12.1 Share of Major Players
13. KEY PLAYERS ANALYSIS
13.1 F. Hoffmann-La Roche AG
13.2 Bristol-Myers Squibb
13.3 Merck & Co., Inc.
13.4 Novartis
13.5 AstraZeneca Plc
13.6 Pfizer Inc
13.7 Eli Lilly and Company
13.8 Johnson & Johnson
13.9 Amgen Inc.
2. RESEARCH METHODOLOGY
3. IMMUNO-ONCOLOGY: OVERVIEW
4. MARKET DYNAMICS
4.1 Drivers
4.1.1 Increasing Cancer Incidences
4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
4.1.3 Growing Geriatric Population
4.1.4 High Healthcare Spending in Developed Economies
4.1.5 Strong Pipeline
4.1.6 Increasing Efficacy in a Wide Variety of Indications
4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
4.2 Challenges
4.2.1 Patent Expiry of Top-Selling Drugs
4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatments
4.2.3 Sky-High Development Costs of Cancer Immunotherapies
4.2.4 High Cost of Treatment
4.2.5 Lack of Awareness
4.3 Opportunities
4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival
4.3.3 CAR-T Therapies: The Future of Cancer Care
4.3.4 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies
5. GLOBAL IMMUNO-ONCOLOGY MARKET OUTLOOK 2024
6. GLOBAL IMMUNO-ONCOLOGY MARKET, BY PRODUCT CLASS
6.1 Monoclonal Antibodies (mAbs)
6.1.1 Naked Monoclonal Antibodies
6.1.1.1 Rituxan (Rituximab)
6.1.1.2 Avastin (Bevacizumab)
6.1.1.3 Herceptin (Trastuzumab)
6.1.2 Conjugated Monoclonal Antibodies
6.1.2.1 ADCETRIS (Brentuximab vedotin)
6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)
6.1.3 Bispecific Monoclonal Antibodies
6.1.3.1 Blincyto (Blinatumomab)
6.1.4 Others
6.2 Therapeutic Vaccines
6.2.1 Provenge
6.3 Immune Checkpoint Inhibitors
6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
6.3.1.1 Yervoy (Ipilimumab)
6.3.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand
6.3.2.1 Opdivo (Nivolumab)
6.3.2.2 Keytruda (Pembrolizumab)
6.4 Others
7. GLOBAL IMMUNO-ONCOLOGY MARKET, BY MAJOR INDICATIONS
7.1 Head & Neck Cancer
7.2 Lung Cancer
7.3 Melanoma
7.4 Lymphoma
7.5 Leukemia
7.6 Others
8. GLOBAL IMMUNO-ONCOLOGY MARKET, BY GEOGRAPHY
8.1 North America
8.2 Europe
8.3 Asia-Pacific
9. TRENDS & DEVELOPMENTS
9.1 Lucrative Investment Trend
9.2 Emergence of Targeted and Combination Therapies
9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
10. STRATEGIC COLLABORATIONS & ALLIANCES IN THE IMMUNO-ONCOLOGY INDUSTRY
11. PIPELINE ANALYSIS OF IMMUNO-ONCOLOGY
12. COMPETITIVE LANDSCAPE
12.1 Share of Major Players
13. KEY PLAYERS ANALYSIS
13.1 F. Hoffmann-La Roche AG
13.2 Bristol-Myers Squibb
13.3 Merck & Co., Inc.
13.4 Novartis
13.5 AstraZeneca Plc
13.6 Pfizer Inc
13.7 Eli Lilly and Company
13.8 Johnson & Johnson
13.9 Amgen Inc.
LIST OF FIGURES:
Figure 4-1: Global - Cancer Incidences (Million), 2020, 2025, 2030, 2035 & 2040
Figure 4-2: Global - Cancer Mortality (Million) 2020, 2025, 2030, 2035 & 2040
Figure 4-3: Global - Population above 65 Years (Billion), 2019 & 2050
Figure 5-1: Global - Immuno-Oncology Market (Billion US$), 2018-2024
Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%), 2019
Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%), 2024
Figure 6-3: Global - Monoclonal Antibodies Market (Billion US$), 2018-2024
Figure 6-4: Global - Rituxan Market (Million US$), 2016-2019
Figure 6-5: Global - Avastin Market (Million US$), 2016-2019
Figure 6-6: Global - Herceptin Market (Million US$), 2016-2019
Figure 6-7: Global - ADCETRIS Market (Million US$), 2016-2019
Figure 6-8: Global - Kadcyla Market (Million US$), 2016-2019
Figure 6-9: Global - Blincyto Market (Million US$), 2016-2019
Figure 6-10: Global - Other Monoclonal Antibodies Market (Billion US$), 2018-2024
Figure 6-11: Global - Therapeutic Cancer Vaccines Market (Million US$), 2018-2024
Figure 6-12: Global - Provenge Market (Million US$), 2016-2019
Figure 6-13: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2018-2024
Figure 6-14: Global - Yervoy Market (Million US$), 2016-2019
Figure 6-15: Global - Opdivo Market (Million US$), 2016-2019
Figure 6-16: Global - Keytruda Market (Million US$), 2016-2019
Figure 6-17: Global - Others Immuno-oncology Drugs Market (Billion US$), 2018-2024
Figure 7-1: Global - Share of Immuno-Oncology Market by Application (%), 2019
Figure 7-2: Global - Share of Immuno-Oncology Market by Application (%), 2024
Figure 7-3: Global - Head & Neck Cancer Market (Billion US$), 2018-2024
Figure 7-4: Head & Neck Cancer - Immunotherapy Clinical Studies by Product-class
Figure 7-5: Head & Neck Cancer - Immunotherapy Clinical Studies by Phase
Figure 7-6: Global - Lung Cancer Market (Billion US$), 2018-2024
Figure 7-7: Lung Cancer - Immunotherapy Clinical Studies by Product-class
Figure 7-8: Lung Cancer - Immunotherapy Clinical Studies by Phase
Figure 7-9: Global - Melanoma Market (Billion US$), 2018-2024
Figure 7-10: Melanoma - Immunotherapy Clinical Studies by Product-class
Figure 7-11: Melanoma - Immunotherapy Clinical Studies by Phase
Figure 7-12: Global - Lymphoma Market (Billion US$), 2018-2024
Figure 7-13: Lymphoma - Immunotherapy Clinical Studies by Product-class
Figure 7-14: Lymphoma - Immunotherapy Clinical Studies by Phase
Figure 7-15: Global - Leukemia Market (Billion US$), 2018-2024
Figure 7-16: Leukemia - Immunotherapy Clinical Studies by Product-class
Figure 7-17: Leukemia - Immunotherapy Clinical Studies by Phase
Figure 7-18: Global - Other Cancer Market (Billion US$), 2018-2024
Figure 7-19: Other Cancer - Immunotherapy Clinical Studies by Product-class
Figure 7-20: Other Cancer - Immunotherapy Clinical Studies by Phase
Figure 8-1: Global - Share of Immuno-Oncology Market by Geography (%), 2019
Figure 8-2: Global - Share of Immuno-Oncology Market by Geography (%), 2024
Figure 8-3: North America - Immuno-Oncology Market (Billion US$), 2018-2024
Figure 8-4: Europe - Immuno-Oncology Market (Billion US$), 2018-2024
Figure 8-5: Asia-Pacific - Immuno-Oncology Market (Billion US$), 2018-2024
Figure 11-1: Global - Immuno-Oncology Clinical Studies by Product-class
Figure 11-2: Global - Immuno-Oncology Pipeline Analysis by Phase (%), 2019
Figure 12-1: Global - Share of Key Players in Immuno-Oncology Market (%), 2019
Figure 13-1: F. Hoffmann-La Roche AG - Revenue by Business Segment (%), 2019
Figure 13-2: F. Hoffmann-La Roche AG - Pharmaceutical Division Revenue by Geography (%), 2019
Figure 13-3: Bristol Myers Squibb - Revenue by Geography (%), 2019
Figure 13-4: Merck & Co., Inc. - Revenue by Business Segment (%), 2019
Figure 13-5: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segment (%), 2019
Figure 13-6: Merck & Co., Inc. - Revenue by Geography (%), 2019
Figure 13-7: Novartis - Revenue by Business Segment (%), 2019
Figure 13-8: Novartis - Innovative Medicines Division Revenue by Segment (%), 2019
Figure 13-9: Novartis - Pharmaceuticals Division Revenue by Segment (%), 2019
Figure 13-10: Novartis - Revenue by Geography (%), 2019
Figure 13-11: AstraZeneca Plc - Revenue by Business Segment (%), 2019
Figure 13-12: AstraZeneca Plc - Revenue by Geography (%), 2019
Figure 13-13: Pfizer Inc - Revenue by Business Segment (%), 2019
Figure 13-14: Pfizer Inc - Revenue by Geography (%), 2019
Figure 13-15: Eli Lilly and Company - Revenue by Business Segment (%), 2019
Figure 13-16: Eli Lilly and Company - Human Pharmaceutical Division Revenue by Business Segment (%), 2019
Figure 13-17: Eli Lilly and Company - Revenue by Geography (%), 2019
Figure 13-18: Johnson & Johnson - Revenue by Business Segment (%), 2019
Figure 13-19: Johnson & Johnson - Revenue by Pharmaceutical Segment (%), 2019
Figure 13-20: Johnson & Johnson - Revenue by Geography (%), 2019
Figure 13-21: Amgen Inc. - Revenue by Product (%), 2019
Figure 13-22: Amgen Inc. - Revenue by Geography (%), 2019
Figure 4-1: Global - Cancer Incidences (Million), 2020, 2025, 2030, 2035 & 2040
Figure 4-2: Global - Cancer Mortality (Million) 2020, 2025, 2030, 2035 & 2040
Figure 4-3: Global - Population above 65 Years (Billion), 2019 & 2050
Figure 5-1: Global - Immuno-Oncology Market (Billion US$), 2018-2024
Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%), 2019
Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%), 2024
Figure 6-3: Global - Monoclonal Antibodies Market (Billion US$), 2018-2024
Figure 6-4: Global - Rituxan Market (Million US$), 2016-2019
Figure 6-5: Global - Avastin Market (Million US$), 2016-2019
Figure 6-6: Global - Herceptin Market (Million US$), 2016-2019
Figure 6-7: Global - ADCETRIS Market (Million US$), 2016-2019
Figure 6-8: Global - Kadcyla Market (Million US$), 2016-2019
Figure 6-9: Global - Blincyto Market (Million US$), 2016-2019
Figure 6-10: Global - Other Monoclonal Antibodies Market (Billion US$), 2018-2024
Figure 6-11: Global - Therapeutic Cancer Vaccines Market (Million US$), 2018-2024
Figure 6-12: Global - Provenge Market (Million US$), 2016-2019
Figure 6-13: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2018-2024
Figure 6-14: Global - Yervoy Market (Million US$), 2016-2019
Figure 6-15: Global - Opdivo Market (Million US$), 2016-2019
Figure 6-16: Global - Keytruda Market (Million US$), 2016-2019
Figure 6-17: Global - Others Immuno-oncology Drugs Market (Billion US$), 2018-2024
Figure 7-1: Global - Share of Immuno-Oncology Market by Application (%), 2019
Figure 7-2: Global - Share of Immuno-Oncology Market by Application (%), 2024
Figure 7-3: Global - Head & Neck Cancer Market (Billion US$), 2018-2024
Figure 7-4: Head & Neck Cancer - Immunotherapy Clinical Studies by Product-class
Figure 7-5: Head & Neck Cancer - Immunotherapy Clinical Studies by Phase
Figure 7-6: Global - Lung Cancer Market (Billion US$), 2018-2024
Figure 7-7: Lung Cancer - Immunotherapy Clinical Studies by Product-class
Figure 7-8: Lung Cancer - Immunotherapy Clinical Studies by Phase
Figure 7-9: Global - Melanoma Market (Billion US$), 2018-2024
Figure 7-10: Melanoma - Immunotherapy Clinical Studies by Product-class
Figure 7-11: Melanoma - Immunotherapy Clinical Studies by Phase
Figure 7-12: Global - Lymphoma Market (Billion US$), 2018-2024
Figure 7-13: Lymphoma - Immunotherapy Clinical Studies by Product-class
Figure 7-14: Lymphoma - Immunotherapy Clinical Studies by Phase
Figure 7-15: Global - Leukemia Market (Billion US$), 2018-2024
Figure 7-16: Leukemia - Immunotherapy Clinical Studies by Product-class
Figure 7-17: Leukemia - Immunotherapy Clinical Studies by Phase
Figure 7-18: Global - Other Cancer Market (Billion US$), 2018-2024
Figure 7-19: Other Cancer - Immunotherapy Clinical Studies by Product-class
Figure 7-20: Other Cancer - Immunotherapy Clinical Studies by Phase
Figure 8-1: Global - Share of Immuno-Oncology Market by Geography (%), 2019
Figure 8-2: Global - Share of Immuno-Oncology Market by Geography (%), 2024
Figure 8-3: North America - Immuno-Oncology Market (Billion US$), 2018-2024
Figure 8-4: Europe - Immuno-Oncology Market (Billion US$), 2018-2024
Figure 8-5: Asia-Pacific - Immuno-Oncology Market (Billion US$), 2018-2024
Figure 11-1: Global - Immuno-Oncology Clinical Studies by Product-class
Figure 11-2: Global - Immuno-Oncology Pipeline Analysis by Phase (%), 2019
Figure 12-1: Global - Share of Key Players in Immuno-Oncology Market (%), 2019
Figure 13-1: F. Hoffmann-La Roche AG - Revenue by Business Segment (%), 2019
Figure 13-2: F. Hoffmann-La Roche AG - Pharmaceutical Division Revenue by Geography (%), 2019
Figure 13-3: Bristol Myers Squibb - Revenue by Geography (%), 2019
Figure 13-4: Merck & Co., Inc. - Revenue by Business Segment (%), 2019
Figure 13-5: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segment (%), 2019
Figure 13-6: Merck & Co., Inc. - Revenue by Geography (%), 2019
Figure 13-7: Novartis - Revenue by Business Segment (%), 2019
Figure 13-8: Novartis - Innovative Medicines Division Revenue by Segment (%), 2019
Figure 13-9: Novartis - Pharmaceuticals Division Revenue by Segment (%), 2019
Figure 13-10: Novartis - Revenue by Geography (%), 2019
Figure 13-11: AstraZeneca Plc - Revenue by Business Segment (%), 2019
Figure 13-12: AstraZeneca Plc - Revenue by Geography (%), 2019
Figure 13-13: Pfizer Inc - Revenue by Business Segment (%), 2019
Figure 13-14: Pfizer Inc - Revenue by Geography (%), 2019
Figure 13-15: Eli Lilly and Company - Revenue by Business Segment (%), 2019
Figure 13-16: Eli Lilly and Company - Human Pharmaceutical Division Revenue by Business Segment (%), 2019
Figure 13-17: Eli Lilly and Company - Revenue by Geography (%), 2019
Figure 13-18: Johnson & Johnson - Revenue by Business Segment (%), 2019
Figure 13-19: Johnson & Johnson - Revenue by Pharmaceutical Segment (%), 2019
Figure 13-20: Johnson & Johnson - Revenue by Geography (%), 2019
Figure 13-21: Amgen Inc. - Revenue by Product (%), 2019
Figure 13-22: Amgen Inc. - Revenue by Geography (%), 2019
LIST OF TABLES:
Table 4-1: Immuno-Oncology - Late Stage Research Pipeline
Table 4-2: US & Europe - Major Drug Patent Expiry in Immuno-Oncology Market
Table 6-1: Ongoing Trials for Rituxan
Table 6-2: Ongoing Trials for Avastin
Table 6-3: Ongoing Trials for Herceptin
Table 6-4: Ongoing Trials for ADCETRIS
Table 6-5: Ongoing Trials for Kadcyla
Table 6-6: Ongoing Trials for Blincyto
Table 6-7: Ongoing Trials for Provenge
Table 6-8: Ongoing Trials for Yervoy
Table 6-9: Ongoing Trials for Opdivo
Table 6-10: Ongoing Trials for Keytruda
Table 7-1: Global - Oncology Incidence by Geography (‘000), 2020 & 2025
Table 9-1: Selected Immuno-Oncology and/or Targeted Therapy Combinations
Table 10-1: Strategic Collaborations in the Immuno-Oncology Industry
Table 11-1: Global - Immuno-Oncology Product Pipeline
Table 13-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2017-2019
Table 13-2: F. Hoffmann-La Roche AG - Commercialized Immuno-Oncology Products
Table 13-3: F. Hoffmann-La Roche AG - Product Pipeline
Table 13-4: Bristol Myers Squibb - Key Financials (Billion US$), 2017-2019
Table 13-5: Bristol Myers Squibb - Commercialized Immuno-Oncology Products
Table 13-6: Bristol Myers Squibb - Product Pipeline
Table 13-7: Merck & Co., Inc. - Key Financials (Billion US$), 2017-2019
Table 13-8: Merck & Co., Inc. - Commercialized Immuno-Oncology Products
Table 13-9: Merck & Co., Inc. - Product Pipeline
Table 13-10: Novartis - Key Financials (Billion US$), 2017-2019
Table 13-11: Novartis - Commercialized Immuno-Oncology Products
Table 13-12: Novartis - Product Pipeline
Table 13-13: AstraZeneca Plc - Key Financials (Billion US$), 2017-2019
Table 13-14: AstraZeneca Plc - Commercialized Immuno-Oncology Products
Table 13-15: AstraZeneca Plc - Product Pipeline
Table 13-16: Pfizer Inc - Key Financials (Billion US$), 2017-2019
Table 13-17: Pfizer Inc - Commercialized Immuno-Oncology Products
Table 13-18: Pfizer Inc - Product Pipeline
Table 13-19: Eli Lilly and Company - Key Financials (Billion US$), 2017-2019
Table 13-20: Eli Lilly and Company - Commercialized Immuno-Oncology Products
Table 13-21: Eli Lilly and Company - Product Pipeline
Table 13-22: Johnson & Johnson - Key Financials (Billion US$), 2017-2019
Table 13-23: Johnson & Johnson - Commercialized Immuno-Oncology Products
Table 13-24: Johnson & Johnson - Product Pipeline
Table 13-25: Amgen Inc. - Key Financials (Billion US$), 2017-2019
Table 13-26: Amgen Inc. - Commercialized Immuno-Oncology Products
Table 13-27: Amgen Inc. - Product Pipeline
Table 4-1: Immuno-Oncology - Late Stage Research Pipeline
Table 4-2: US & Europe - Major Drug Patent Expiry in Immuno-Oncology Market
Table 6-1: Ongoing Trials for Rituxan
Table 6-2: Ongoing Trials for Avastin
Table 6-3: Ongoing Trials for Herceptin
Table 6-4: Ongoing Trials for ADCETRIS
Table 6-5: Ongoing Trials for Kadcyla
Table 6-6: Ongoing Trials for Blincyto
Table 6-7: Ongoing Trials for Provenge
Table 6-8: Ongoing Trials for Yervoy
Table 6-9: Ongoing Trials for Opdivo
Table 6-10: Ongoing Trials for Keytruda
Table 7-1: Global - Oncology Incidence by Geography (‘000), 2020 & 2025
Table 9-1: Selected Immuno-Oncology and/or Targeted Therapy Combinations
Table 10-1: Strategic Collaborations in the Immuno-Oncology Industry
Table 11-1: Global - Immuno-Oncology Product Pipeline
Table 13-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2017-2019
Table 13-2: F. Hoffmann-La Roche AG - Commercialized Immuno-Oncology Products
Table 13-3: F. Hoffmann-La Roche AG - Product Pipeline
Table 13-4: Bristol Myers Squibb - Key Financials (Billion US$), 2017-2019
Table 13-5: Bristol Myers Squibb - Commercialized Immuno-Oncology Products
Table 13-6: Bristol Myers Squibb - Product Pipeline
Table 13-7: Merck & Co., Inc. - Key Financials (Billion US$), 2017-2019
Table 13-8: Merck & Co., Inc. - Commercialized Immuno-Oncology Products
Table 13-9: Merck & Co., Inc. - Product Pipeline
Table 13-10: Novartis - Key Financials (Billion US$), 2017-2019
Table 13-11: Novartis - Commercialized Immuno-Oncology Products
Table 13-12: Novartis - Product Pipeline
Table 13-13: AstraZeneca Plc - Key Financials (Billion US$), 2017-2019
Table 13-14: AstraZeneca Plc - Commercialized Immuno-Oncology Products
Table 13-15: AstraZeneca Plc - Product Pipeline
Table 13-16: Pfizer Inc - Key Financials (Billion US$), 2017-2019
Table 13-17: Pfizer Inc - Commercialized Immuno-Oncology Products
Table 13-18: Pfizer Inc - Product Pipeline
Table 13-19: Eli Lilly and Company - Key Financials (Billion US$), 2017-2019
Table 13-20: Eli Lilly and Company - Commercialized Immuno-Oncology Products
Table 13-21: Eli Lilly and Company - Product Pipeline
Table 13-22: Johnson & Johnson - Key Financials (Billion US$), 2017-2019
Table 13-23: Johnson & Johnson - Commercialized Immuno-Oncology Products
Table 13-24: Johnson & Johnson - Product Pipeline
Table 13-25: Amgen Inc. - Key Financials (Billion US$), 2017-2019
Table 13-26: Amgen Inc. - Commercialized Immuno-Oncology Products
Table 13-27: Amgen Inc. - Product Pipeline
